Clinical trials: KRAS G12V
Advanced Solid Tumors
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
- Trial name
- NCT06715124
- Testing
- QTX3544, Cetuximab
- Where
- 10 sites in United States
- Volunteers
- 237 people
- Sponsor
- Quanta Therapeutics
Tumor, Solid
NW-301 TCR-T in Patients With Advanced Solid Tumor
An open label, two cohorts, multiple dose exploratory clinical study to independently evaluate the safety, efficacy, and pharmacokinetics of autologous anti-KRAS G12V/G12D mutation T-cell Receptor T cell in advanced solid tumor
- Trial name
- NCT06956261
- Testing
- NW-301V, Drug: NW-301D
- Where
- 2 sites in China
- Volunteers
- 44 people
- Sponsor
- Peking University
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
- Trial name
- NCT06105021
- Testing
- AFNT-211
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Affini-T Therapeutics, Inc.
Pancreatic Cancer
A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
This is a single-arm, open-label clinical study to evaluate the safety, tolerability and preliminary efficacy of IX001 TCR-T injection in advanced pancreatic cancer patients with KRAS G12V mutation.
- Trial name
- IX001 TCR-T (NCT06898385)
- Testing
- IX001 TCR-T injection, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06447662
- Testing
- PF-07934040, Gemcitabine, Nab-paclitaxel
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- Pfizer
Pancreatic Cancer, Gastric Cancer
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Background: A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person.
- Conditions
- Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer, Colon Cancer
- Trial name
- NCT03190941
- Testing
- Cyclophosphamide, Fludarabine, Anti-KRAS G12V mTCR PBL
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Ductal Adenocarcinoma, KRAS G12D
Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
This is an open-label expanded access protocol (EAP) of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides 7P])…
- Conditions
- Pancreatic Ductal Adenocarcinoma, KRAS G12D, KRAS G12V, KRAS G12S
- Trial name
- AMPLIFY-EAP (NCT07083479)
- Testing
- ELI-002 7P
- Sponsor
- Elicio Therapeutics
Solid Tumor, Non-Small-Cell Lung Cancer
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS.
- Conditions
- Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT07094204
- Testing
- ASP5834, panitumumab
- Where
- 20 sites in United States, France and 2 more
- Volunteers
- 404 people
- Sponsor
- Astellas Pharma Inc
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation
This is a single-arm, multicenter, open-label, Phase 1a/1b dose-escalation and dose-expansion study designed to evaluate the safety, preliminary antitumor activity, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of…
- Conditions
- Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Adenocarcinoma, Lung Adenocarcinoma
- Trial name
- NCT07875920
- Testing
- Fludarabine, Cyclophosphamide, NW-301V
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Neowise Biotechnology
Pancreatic Ductal Adenocarcinoma, Liver Neoplasms
Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer
This is a single-arm, single-center, exploratory clinical study. A total of 20 participants with metastatic pancreatic ductal adenocarcinoma (with liver or lung metastasis) who have experienced disease progression after or are…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Liver Neoplasms, Lung Neoplasms
- Trial name
- NCT07745790
- Testing
- Multimodal Thermal Therapy (MTT) System, KRAS G12V mRNA Vaccine, Sintilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Non-small Cell Lung Cancer, Histiocytic Neoplasm
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer…
- Conditions
- Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
- Trial name
- NCT05786924
- Testing
- S241656, FOLFOX6/FOLFOX7, FOLFIRI
- Where
- 49 sites in United States, Australia and 8 more
- Volunteers
- 554 people
- Sponsor
- Institut de Recherches Internationales Servier
KRAS G12V Mutant Advanced Epithelial Cancers
Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors
This intermediate-size IND will treat participants with incurable, advanced or metastatic cancer, harboring KRAS G12V mutation and appropriate HLA class II match (HLA-DRB1*07:01).
- Trial name
- NCT05389514
- Testing
- Cyclophosphamide, Gemcitabine, Pembrolizumab
- Sponsor
- Providence Health & Services
Pancreatic Cancer, Colorectal Cancer
IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations
This is a single-arm, single-center, open-label clinical study aimed at evaluating the safety and efficacy of IX001 TCR-T (T cell receptor-engineered T-Cell) injection in patients with advanced pancreatic cancer and colorectal…
- Trial name
- NCT06487377
- Testing
- IX001 TCR-T cells
- Where
- China
- Sponsor
- Shanghai Pudong Hospital
Advanced Solid Tumors
Treatment of Patients With Advanced Solid Tumors Using CRTKVA11-03 TCR-T Cell Injection
This is a single-center, open-label, single-arm, dose-escalation study aimed at evaluating the safety and preliminary efficacy of KRAS-specific autologous TCR-T cells in patients with advanced solid tumors harboring KRAS G12V…
- Trial name
- NCT07826585
- Testing
- CRTKVA11-03 TCR-T Cell Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT07349537
- Testing
- RMC-5127, daraxonrasib, cetuximab
- Where
- 9 sites in United States
- Volunteers
- 574 people
- Sponsor
- Revolution Medicines, Inc.
KRAS G12V, T Cell Therapy
RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors
At present, there is an urgent need for new drugs for kirsten rat sarcoma viral oncogene (KRAS) mutant tumors in clinic. Preclinical studies support the specificity, safety and anti-tumor activity of RE001.
- Trial name
- NCT06545201
- Testing
- RE001 T cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Metastatic Pancreatic Ductal Adenocarcinoma
Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
The purpose of this study is to determine the safety and efficacy of pan KRAS inhibitor JAB-23E73 in combination with nab-paclitaxel and gemcitabine in participants with metastatic PDAC harboring KRAS gene alterations.
- Trial name
- NCT07640295
- Testing
- JAB-23E73 tablet，nab-paclitaxel，gemcitabine
- Where
- 13 sites in China
- Volunteers
- 80 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
KRAS G12V, KRAS G12D
TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
This is a single-arm, Multicenter, open-label clinical study aimed at evaluating the safety and efficacy of TCR-T injection in patients with advanced solid tumors induced by KRAS mutations.
- Conditions
- KRAS G12V, KRAS G12D, Solid Tumor
- Trial name
- NCT07342738
- Testing
- TCR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumors
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 Monotherapy and in Combination with Other Agents in adult participants with advanced solid tumors
- Trial name
- NCT06973564
- Testing
- JAB-23E73, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 344 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.